Cargando…
Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
Acute lung injury and acute respiratory distress syndrome (ARDS) represent a heterogenous group of lung disease in critically ill patients that continues to have high mortality. Despite the increased understanding of the molecular pathogenesis of ARDS, specific targeted treatments for ARDS have yet...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945951/ https://www.ncbi.nlm.nih.gov/pubmed/31988911 http://dx.doi.org/10.1159/000477086 |
_version_ | 1783485267696418816 |
---|---|
author | Sadikot, Ruxana T. Kolanjiyil, Arun V. Kleinstreuer, Clement Rubinstein, Israel |
author_facet | Sadikot, Ruxana T. Kolanjiyil, Arun V. Kleinstreuer, Clement Rubinstein, Israel |
author_sort | Sadikot, Ruxana T. |
collection | PubMed |
description | Acute lung injury and acute respiratory distress syndrome (ARDS) represent a heterogenous group of lung disease in critically ill patients that continues to have high mortality. Despite the increased understanding of the molecular pathogenesis of ARDS, specific targeted treatments for ARDS have yet to be developed. ARDS represents an unmet medical need with an urgency to develop effective pharmacotherapies. Multiple promising targets have been identified that could lead to the development of potential therapies for ARDS; however, they have been limited because of difficulty with the mode of delivery, especially in critically ill patients. Nanobiotechnology is the basis of innovative techniques to deliver drugs targeted to the site of inflamed organs, such as the lungs. Nanoscale drug delivery systems have the ability to improve the pharmacokinetics and pharmacodynamics of agents, allowing an increase in the biodistribution of therapeutic agents to target organs and resulting in improved efficacy with reduction in drug toxicity. Although attractive, delivering nanomedicine to lungs can be challenging as it requires sophisticated systems. Here we review the potential of novel nanomedicine approaches that may prove to be therapeutically beneficial for the treatment of this devastating condition. |
format | Online Article Text |
id | pubmed-6945951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-69459512020-01-27 Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome Sadikot, Ruxana T. Kolanjiyil, Arun V. Kleinstreuer, Clement Rubinstein, Israel Biomed Hub Review Acute lung injury and acute respiratory distress syndrome (ARDS) represent a heterogenous group of lung disease in critically ill patients that continues to have high mortality. Despite the increased understanding of the molecular pathogenesis of ARDS, specific targeted treatments for ARDS have yet to be developed. ARDS represents an unmet medical need with an urgency to develop effective pharmacotherapies. Multiple promising targets have been identified that could lead to the development of potential therapies for ARDS; however, they have been limited because of difficulty with the mode of delivery, especially in critically ill patients. Nanobiotechnology is the basis of innovative techniques to deliver drugs targeted to the site of inflamed organs, such as the lungs. Nanoscale drug delivery systems have the ability to improve the pharmacokinetics and pharmacodynamics of agents, allowing an increase in the biodistribution of therapeutic agents to target organs and resulting in improved efficacy with reduction in drug toxicity. Although attractive, delivering nanomedicine to lungs can be challenging as it requires sophisticated systems. Here we review the potential of novel nanomedicine approaches that may prove to be therapeutically beneficial for the treatment of this devastating condition. S. Karger AG 2017-06-27 /pmc/articles/PMC6945951/ /pubmed/31988911 http://dx.doi.org/10.1159/000477086 Text en Copyright © 2017 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Review Sadikot, Ruxana T. Kolanjiyil, Arun V. Kleinstreuer, Clement Rubinstein, Israel Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome |
title | Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome |
title_full | Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome |
title_fullStr | Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome |
title_full_unstemmed | Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome |
title_short | Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome |
title_sort | nanomedicine for treatment of acute lung injury and acute respiratory distress syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945951/ https://www.ncbi.nlm.nih.gov/pubmed/31988911 http://dx.doi.org/10.1159/000477086 |
work_keys_str_mv | AT sadikotruxanat nanomedicinefortreatmentofacutelunginjuryandacuterespiratorydistresssyndrome AT kolanjiyilarunv nanomedicinefortreatmentofacutelunginjuryandacuterespiratorydistresssyndrome AT kleinstreuerclement nanomedicinefortreatmentofacutelunginjuryandacuterespiratorydistresssyndrome AT rubinsteinisrael nanomedicinefortreatmentofacutelunginjuryandacuterespiratorydistresssyndrome |